.....T his is the first case of PRES during ipilimumab therapy. Increasing awareness of PRES is needed in patients who undergo anti–CTLA-4 therapies and develop irAEs such as hypophysitis in our patient. Autoimmune disorders are associated with an increased risk of PRES; autoimmune hypophysitis, however, does not seem to be implicated in the development of PRES. Further inves- tigations on the mechanisms of toxicity and risk factors for PRES are necessary
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Data di pubblicazione: | 2012 | |
Titolo: | Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma | |
Autori: | Maur, Michela; Tomasello, Chiara; Frassoldati, Antonio; Dieci, Maria Vittoria; Barbieri, Elena; Conte, Pierfranco | |
Rivista: | JOURNAL OF CLINICAL ONCOLOGY | |
Parole Chiave: | Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Melanoma; Middle Aged; Posterior Leukoencephalopathy Syndrome; Skin Neoplasms; Vaginal Neoplasms; Cancer Research; Oncology | |
Abstract in inglese: | .....T his is the first case of PRES during ipilimumab therapy. Increasing awareness of PRES is needed in patients who undergo anti–CTLA-4 therapies and develop irAEs such as hypophysitis in our patient. Autoimmune disorders are associated with an increased risk of PRES; autoimmune hypophysitis, however, does not seem to be implicated in the development of PRES. Further inves- tigations on the mechanisms of toxicity and risk factors for PRES are necessary | |
Digital Object Identifier (DOI): | 10.1200/JCO.2011.38.7886 | |
Handle: | http://hdl.handle.net/11392/2377819 | |
Appare nelle tipologie: | 03.1 Articolo su rivista |
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.